Director, BD Early Stage

The Director, BD Early Stage leads the assessment of early-stage external innovation opportunities from Due Diligence Stage 2 to negotiation of a Non-Binding Offer (NBO). The role integrates evolving scientific advances, therapeutic trends and market dynamics to guide CSL's long-range BD investment decisions in early-stage opportunities. It provides deep subject-matter leadership and enterprise-level judgement to ensure potential partnerships and acquisitions advance CSL’s portfolio impact, scientific differentiation and competitive positioning.

• Lead evaluation of early-stage external assets, technologies, platforms and modalities aligned to TA Strategy from Due Diligence Stage 2 through Governance to negotiation of NBO.

• Integrate scientific, clinical, mechanistic, regulatory and commercial evidence into holistic assessments of attractiveness, differentiation and enterprise and TA strategic fit.

• Deliver investment-quality inputs such as valuation assumptions, scenario modelling, unmet need assessments, deal analogues and downstream implications (e.g., biomarker requirements, specialized development pathways, manufacturing needs).

• Translate complex scientific and clinical narratives into clear, concise and decision-ready recommendations for CSL senior leaders.

• Provide recommendations on progressing, deferring or declining opportunities based on enterprise priorities and the TA Strategy.

• Apply CSL’s evaluation standards and prioritization frameworks to ensure rigor, consistency and balanced risk-benefit assessment.

• Develop and maintain key external partnerships with potential partners in close collaboration with R&D Search.

• Partner with BD Transactions to shape valuation logic, risk scenarios, deal structures and diligence readiness for advanced opportunities.

• Engage with global cross-functional partners including Commercial, Medical, Clinical Development, Regulatory, Technical Operations, Strategy, Finance to inform integrated and robust evaluation outputs.

• Prepare high-quality evaluation summaries, strategic assessments and decision papers for enterprise governance (e.g. PRISM, REDC) and other senior bodies as needed (e.g. PDCa, IDC).

• Ensure evaluation outputs reflect analytical depth, strategic clarity, scientific credibility and integrated cross-functional perspectives.

• Support enterprise capital allocation and portfolio shaping discussions with clear strategic logic and evidence-driven recommendations.

• Strengthen organizational capability in scientific evaluation, market analysis, disease modelling and structured diligence within the BD function.

• Bachelor’s degree in Life Sciences, Medicine, Pharmacy, Biology, Physiology or a related discipline (required);
  Advanced degree such as PhD, MD, PharmD, MSc, MBA, or equivalent scientific/commercial qualification (strongly preferred).

• 5-10+ years in pharmaceutical/biotechwith substantive exposure to Search &Evaluation, early‑stage BD, R&D strategy or new product planning

• Proven ability to assess scientific/commercial potential and influence governance decisions

• Demonstrated success evaluating external opportunities, leading negotiations and influencing cross-functional and senior-level decisions

• Experience partnering across R&D, Commercial, Finance, Regulatory, and Transactions in a global matrix

• Proven abilitysupportinginvestment cases and contribute meaningfully to diligence and strategic evaluations

• Strong scientific…